Martin Tom

Join us at the 108th Annual Meeting for expert-led discussions on advancing care in gynecologic oncology, including cutting-edge research and real-world treatment insights. Don’t miss this opportunity to learn from leaders in the field - americanradiumsociety.org/page/108Annual…

Explore the future of radiation oncology at the Theranostics, Bio & Physics Education Session during the 108th Annual Meeting. Don’t miss this opportunity to learn and connect with from leaders in the field at the premier gathering of the ARS in Newport Beach this May. 🚀

Treatment for Brain Metastases With Stereotactic Radiation vs Hippocampal-Avoidance Whole Brain Radiation A Randomized Clinical Trial jamanetwork.com/journals/jama/…

📣 Registration is OPEN for the ARS 108th Annual Meeting! Join us April 30-May 3, 2026, in Newport Beach, CA. Early-bird rates end Jan 31. Don’t miss out! americanradiumsociety.org/events/EventDe…

Preach! It really is simple math, and thankfully, modern OligoSBRT has a strong Safety and Efficacy track record. Shout-out to @ScarboroughJess et al. and @EricLehrer et al. for clearly demonstrating each piece of the puzzle. #radonc

Submit your #ARS2026 abstract today!⏳⏰☀️

Honored to recognize Daphne Haas-Kogan, MD, MBA, FASTRO, FACR as this year’s Janeway Medal recipient! As a leader in pediatric & brain tumor research, mentor, and advocate for advancing women in medicine, her impact is profound.

Radiation oncologists are trained to deliver safe, high-precision radiotherapy as part of a #cancer care team. We follow the best available evidence & develop customized, cost-effective plans. Science guides our treatments, but humanity guides our practice. 1/2

Excited to share our summary of metabolic cell death pathways relevant for cancer therapy. @NatureRevCancer #endcancer

⚡️ BREAKTHROUGH OR JUST BARELY THERE? #METIS Ph. 3 RCT presented at #ASTRO25 Plenary earlier this week (Tumor Treating Fields, TTF, after SRS for #lungcancer brain mets) revealed TTF significantly delayed intracranial progression ✅ But when you dig into the results - especially the study appendix - the story isn’t so simple 👇 Just finished reading the full METIS manuscript + appendix (PMID: 41033612) published in @IJROBP First, HUGE thank you and congrats to the authors on completing this landmark study 👏 📌 Quick refresher on study design/results • Phase III, 298 pts • Open-label, randomized 1:1 • TTF+SRS ⚡ vs SRS alone 🎯 • Primary endpoint = Time to Intracranial Progression (TTIP) ⏱ • Median follow-up = 8.6 mo • ✅️ TTF significantly delayed TTIP (HR 0.72, p=0.044) → ~28% ↓ risk of intracranial progression • Side effect profile favorable, mostly grade 1–2 Sounds encouraging, right? Well… let’s look closer 👀 🧩 What exactly was TTIP? A composite of 4 components: 1️⃣ Local progression 2️⃣ Clinical worsening 3️⃣ Neurologic death 4️⃣ Distant progression 📑 Now, here is the catch (Figure S3 in the appendix): 👉 NONE of the 4 components were individually significant ❌ Local progression NS ❌ (HR 0.82, p=0.44) Clinical worsening NS ❌ (HR 1.04, p=0.96) Neurologic death NS ❌ (HR 1.02, p=0.69) Distant progression NS ❌ (HR 0.76, p=0.17) ⚠️ The “win” came only from combining 4 components, none of which were statistically significant on their own. 🧐 But how about secondary endpoints? There is some good news there, right? Well… not quite 😬 OS 💀 = negative Cognition 🧠 = negative QoL 📉 = negative So the entire “positive” signal rests on the composite itself, leaving open the question of whether this reflects true clinical benefit for patients... 🙌 Final thoughts: I’m glad we now have another potential option for #lungcancer brain metastases🌟 Huge respect to the METIS investigators 👏 - pulling off such a massive Phase 3 trial in this space is an enormous achievement 💪 But with no OS benefit and TTIP met only by pooling 4 non-significant components and right at the 0.05 threshold, one may wonder if this intervention actually translates into meaningful patient benefit, or if the signal is more statistical than clinical... Curious what others think ⬇️ And regardless - credit where it’s due 🙏: this is still an important new treatment tool, and pulling off METIS was a milestone worth celebrating 👏🌍⚡ #radonc #TTF #Optune #Novocure

@StasLazarev Great Nature Review of this topic by @StasLazarev. Thanks for coming to the talk! nature.com/articles/s4157…

👏 Outstanding, balanced review by @MartinTomMD calling out #Vorasidenib hype in INDIGO (RCT of Vorasidenib vs Placebo for low grade glioma (LGG) patients with gross disease (i.e. high-risk LGG) INDIGO data (IDH-mut LGG): ▶️ORR: 0% CR, 1% PR, 10% MR, 83% SD ▶️23% grade ≥3 tox (mostly ↑ LFTs) ▶️Never compared to RT+PCV/TMZ - only placebo ▶️Cross-over allowed (placebo patients were deprived standard of therapy chemoRT twice [at randomization, and at progression] ▶️82% placebo patients progressed at 2 years (these patients should NOT have been observed in the first place) ▶️Short follow-up (14 mo.) RT toxicities in LGGs often overstated, especially in the context of modern RT techniques (IMRT, VMAT, protons): 🔷️Radiation necrosis ~2% 🔷️Absolute risk of stroke is exceedingly low 🔷️Hormone dysfunction only with significant hypothalamic/pituitary dose (and is a fixable issue); uncommon with modern conformal RT 🔷️Prospective cognitive studies: most show no sustained decline; when seen, often due to tumor progression, not RT 👉 Painting RT as a toxic treatment for LGGs while overselling modest to negligible INDIGO results is misleading for patients and physicians #ASTRO25 #RadOnc #NeuroOnc

Cleveland Clinic residents are so proud to announce the publication of the third edition of Essentials of Clinical Radiation Oncology (ie the Redbook!). Grab your copy now!! @springerpub #description" target="_blank" rel="nofollow noopener">springerpub.com/essentials-of-… @RTendulkarMD @MCWardMD

☀️Sun, science, and the future of oncology - the abstract submission site for #ARS2026 is now officially open! Join us April 30-May 3, 2026 at the Pendry Hotel in Newport Beach, CA and get ready to network and share your science!🧬

⭐️Abstract submissions for #ARS2026 open Sept 15 2025⭐️ Join us in beautiful Newport Beach, CA 🌊 at the Pendry Hotel, April 30-May3, 2026! Don’t miss the chance to share your work and connect with colleagues ✨

Does the addition of MDT to standard of care continuous ADT improve outcomes for oligomet prostate ca? Happy to share the results of EXTEND evaluating this question alongside PI @ChadTangMD & many others

🚨 We’re hiring not one but TWO medical oncologists in Parkersburg, WV, a welcoming community with real need, a big heart, and a team that’s ready to support you. A chance to truly make a difference in a community of need: wvumedicine.wd1.myworkdayjobs.com/UHA/job/Camden…

And wonderful to see so many friends in town!

congratulations @StephDudzinski ARS award! Eric Chang and Simon Lo

⁦@RadiumSociety⁩ Special Session on SBRT for epidural spinal cord compression ⁦@SahgalArjun⁩ ⁦@MichaelTMilano⁩ Larry Rhines